Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer

Bristol Myers Squibb has worked overtime to hunt down an edge for its PD-(L)1 blocker Opdivo over rival Keytruda from Merck, including taking a bold combo strategy with CTLA4 inhibitor Yervoy. But in head and neck cancer, the combo keeps dropping duds.